Articles tagged "Induction therapy"

2019 American Transplant Congress
Association Of Lymphocyte-depleting Antibody And Steroids Induction With The Risk And Outcomes Of Post-transplant Diabetes: Analysis Of Deceased-donor Kidney Transplants
A. Santos¹, J. Gregg², U. L. Akanit³, K. Alquadan¹, H. Bejjanki¹, K. L. Womer¹
¹Div. of Nephrology, Hypertension & Renal Transplantation, University of Florida, Gainesville, FL, ²University of Florida, Gainesville, FL, ³Ubon Ratchathani University, Ubonratchathani, Thailand
*Purpose: We aimed to determine the risk and outcomes of post-transplant diabetes(PTDM) associated with combined lymphocyte-depleting antibody (LDA) [anti-thymocyte globulin (ATG) or alemtuzumab (ALM)] and…
2019 American Transplant Congress
Combined Antithymocyte Globulin (ATG) and Rituximab (RTX) Induction in African American (AA) Kidney Transplant Recipients
S. J. Patel, S. Kuten, C. Pham, R. Knight, M. Hobeika, D. Nguyen, E. Graviss, S. Yi, T. Eagar, A. Gaber
Methodist Hospital, Houston, TX
*Purpose: We have previously shown that despite the use of T cell-depleting antibody induction, AA kidney transplant recipients (KTR) remain at high risk of rejection…
2019 American Transplant Congress
Comparison of Basiliximab and Alemtuzumab for Lung Transplant Induction
S. Mietz¹, D. Roe², E. Lushin¹, E. Anderson¹, C. Hage²
¹Pharmacy, Indiana University Health, Indianapolis, IN, ²Pulmonary Critical Care, Indiana University Health, Indianapolis, IN
*Purpose: Compare alemtuzumab and basiliximab used for lung transplant in terms of rejection, CLAD, and mortality.*Methods: A retrospective review of lung transplants performed between 2010…
2019 American Transplant Congress
Basiliximab versus T-cell Depleting Induction Therapy in Elderly Kidney Transplant Recipients
G. Vranic, H. Shah, B. Thomas, B. Javaid, J. Moore, M. Cooper, A. Gilbert
MedStar Georgetown Transplant Institute, Washington, DC
*Purpose: The ideal induction therapy for elderly kidney transplant recipients is not known. Given concerns about increased risk of infection and malignancy and perceived decreased…
2019 American Transplant Congress
Safety Outcomes in Elderly Patients Who Receive Alemtuzumab Induction for Kidney Transplant
S. Anders, A. Freeman, A. Mohammed, L. Hutchinson, U. Kaszubski, M. Janusek, J. Garces, H. Bohorquez
Ochsner Clinic Foundation, New Orleans, LA
*Purpose: As a consequence of natural immunosenescence, elderly patients may not require as potent immunosuppression as their younger counterparts. Optimal induction regimens in this population,…
2019 American Transplant Congress
Use of an Ideal Body Weight-Based Rabbit Anti-Thymocyte Globulin Dosing Protocol in Kidney Transplant Recipients to Decrease Cost and Maintain Outcomes at a Large Academic Medical Center
L. J. Myhre¹, R. J. Bubik¹, K. T. Peterson¹, H. A. Personett¹, S. A. Crow¹, P. G. Dean²
¹Pharmacy, Mayo Clinic, Rochester, MN, ²Transplantation Surgery, Mayo Clinic, Rochester, MN
*Purpose: This quality improvement study sought to assess if rejection post-transplant was increased following implementation of an ideal body weight (IBW)-based dosing protocol for patients…
2019 American Transplant Congress
Is Alemtuzumab Induction Safe In Septuagenarians Undergoing Deceased Donor Kidney Transplantation?
D. Harriman, V. Gurram, C. Jay, J. Rogers, A. Farney, G. Orlando, A. Reeves-Daniel, A. Mena-Gutierrez, R. Stratta
Wake Forest Baptist Medical Center, Winston-Salem, NC
*Purpose: Alemtuzumab induction in septuagenarians is controversial but understudied.*Methods: Single center retrospective review of adult deceased donor kidney transplant (KT) recipients receiving single dose (30…
2019 American Transplant Congress
Induction Type Does Not Influence Kidney Graft or Patient Survival in Recipients with a Previous Heart Transplant in the United States
S. M. Riad¹, A. Tamas¹, S. Jackson², C. Martin¹
¹Medicine, University of Minnesota, Minneapolis, MN, ²Complex Care Analytics, Fairview Health Services, Minneapolis, MN
*Purpose: Induction regimens for kidney transplant (KT) in heart recipients vary widely among transplant centers. We sought to examine the impact of kidney induction type…
2019 American Transplant Congress
Reduced Intensity Induction Therapy in Patients Undergoing Repeat Kidney Transplants
K. Linhares, M. Cristelli, C. Felipe, L. Viana, H. Proença, R. E. de Marco, J. Pestana, H. Tedesco
Hospital do Rim, Nephrology Division, EPM - UNIFESP, São Paulo, Brazil
*Purpose: We hypothesized that patients without donor-specific antibodies (DSA) undergoing repeat transplants could receive lower doses of antithymocyte globulin induction (rATG), without compromising efficacy and…
2019 American Transplant Congress
Depletional Induction Therapy in Non-Human Primates – Preclinical Modeling of Polyclonal Depletion with Rhesus-Specific ATG
R. Schmitz¹, M. S. Mulvihill¹, P. M. Schroder¹, Z. Fitch¹, F. Leopardi¹, D. Magnani², J. Kwun¹, S. J. Knechtle¹, A. D. Kirk¹
¹Surgery, Duke University Medical Center, Durham, NC, ²University of Massachusetts Medical School, Boston, MA
*Purpose: Antithymocyte globulins (ATG) have been used in transplantation since the late 1960s to prevent and treat acute allograft rejection. Over the past decade, induction…